Clinical trials: Ritonavir
COVID-19
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
The purpose of this study is to learn about the effects of the study medicine called Paxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.
- Trial name
- NCT07261085
- Testing
- nirmatrelvir-ritonavir, No treatment
- Where
- United States
- Volunteers
- 99,000 people
- Sponsor
- Pfizer
Advanced Solid Tumours
Extended Use of ModraDoc006/r
This is a study for extended use of ModraDoc006/r in patients with advanced solid tumours, available after completed treatment in one of the phase I trials with ModraDoc006/r.
- Trial name
- NCT03150368
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Modra Pharmaceuticals
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01749150
- Testing
- danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 13 sites in South Korea, Taiwan and 1 more
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Virus (HCV)
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total…
- Trial name
- HEMATITE (NCT03002818)
- Where
- 5 sites in Switzerland
- Volunteers
- 41 people
- Sponsor
- AbbVie
Bioequivalence
Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)
Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson\&Jonson", Russia)
- Trial name
- NCT04268472
- Testing
- GP30101, Prezista®
- Where
- Russia
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Geropharm
Human Immunodeficiency Virus Type 1
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF)…
- Trial name
- NCT02269917
- Testing
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Where
- 79 sites in United States, Belgium and 8 more
- Volunteers
- 1,149 people
- Sponsor
- Janssen R&D Ireland
Healthy
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)
- Trial name
- NCT02226978
- Testing
- Tipranavir, Ritonavir, Valaciclovir
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic…
- Trial name
- NCT02356562
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin
- Volunteers
- 29 people
- Sponsor
- AbbVie
HIV Infections
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients
The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.
- Trial name
- NCT00071097
- Testing
- TMC114/rtv
- Where
- 39 sites in United States, Argentina
- Volunteers
- 330 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Bioequivalence
Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination and a single dose of Test product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination or vice versa…
- Trial name
- Orvical (NCT04386876)
- Testing
- Lopinavir/Ritonavir 200 mg/50 mg Film Tablet, Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- World Medicine ILAC SAN. ve TIC. A.S.
Hepatitis C
A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- NCT01332552
- Testing
- GSK2485852 70 mg, GSK2485852 420 mg, GSK2485852 630 mg
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
The primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone…
- Trial name
- NCT02616783
- Testing
- E/C/F/TAF, TDF, FTC
- Where
- 35 sites in Belgium, France and 3 more
- Volunteers
- 167 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection
This study evaluated the safety, tolerability, antiviral activity, and pharmacokinetics of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adult Japanese patients with…
- Trial name
- NCT01672983
- Testing
- ABT-450/ritonavir, ABT-267
- Volunteers
- 110 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Delta Hepatitis
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
- Trial name
- LOWR-5 (NCT02968641)
- Testing
- Lonafarnib, Ritonavir
- Sponsor
- Eiger BioPharmaceuticals
Chronic Hepatitis B
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects
- Trial name
- NCT03662568
- Testing
- GLS4, RTV, ETV
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.